Automate Your Wheel Strategy on PFE
With Tiblio's Option Bot, you can configure your own wheel strategy including PFE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol PFE
- Rev/Share 11.0067
- Book/Share 15.9713
- PB 1.4731
- Debt/Equity 0.6785
- CurrentRatio 1.2581
- ROIC 0.0897
- MktCap 133321926500.0
- FreeCF/Share 1.665
- PFCF 14.1096
- PE 16.9182
- Debt/Assets 0.2946
- DivYield 0.0725
- ROE 0.0878
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Initiation | PFE | Cantor Fitzgerald | -- | Neutral | -- | $24 | April 22, 2025 |
| Resumed | PFE | BofA Securities | -- | Neutral | -- | $29 | Dec. 10, 2024 |
| Initiation | PFE | Bernstein | -- | Market Perform | -- | $32 | Oct. 17, 2024 |
News
Pfizer CEO says tariff uncertainty is deterring further U.S. investment in manufacturing, R&D
Published: April 29, 2025 by: CNBC
Sentiment: Negative
It comes as drugmakers brace for Trump's levies on pharmaceuticals imported into the U.S. – his administration's bid to boost manufacturing in the country.
Read More
Pfizer Q1 Earnings Beat Estimates, Several Headwinds Hurt Sales
Published: April 29, 2025 by: Zacks Investment Research
Sentiment: Positive
PFE beats first-quarter estimates for earnings but misses the same for sales. It maintains 2025 guidance.
Read More
Crude Oil Down Over 2%; Pfizer Shares Gain After Q1 Earnings
Published: April 29, 2025 by: Benzinga
Sentiment: Neutral
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining over 250 points on Tuesday.
Read More
Trade Balance in Goods Hits All-Time Record, Plus Q1 Earnings
Published: April 29, 2025 by: Zacks Investment Research
Sentiment: Positive
Pre-market futures are mixed-to-flat once again, this time with the blue-chip Dow leading into positive territory.
Read More
Pfizer Revenue Slides as Paxlovid Sales Fade
Published: April 29, 2025 by: WSJ
Sentiment: Negative
Pfizer recorded lower first-quarter revenue on a 75% drop in sales of its Covid-19 treatment, which more than offset growth in other drugs and product categories.
Read More
Pfizer Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street's Most Accurate Analysts
Published: April 29, 2025 by: Benzinga
Sentiment: Neutral
Pfizer Inc. PFE will release earnings results for the first quarter, before the opening bell on Tuesday, April 29.
Read More
Will These 5 Big Drug Stocks Surpass Q1 Earnings Forecasts?
Published: April 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Let's look at five pharma and drug companies, PFE, LLY, AMGN, BIIB and REGN, which are scheduled to release their first-quarter 2025 results later this week.
Read More
4 Top Value Stocks to Invest in as US-Global Trade Talks Unfold
Published: April 28, 2025 by: Zacks Investment Research
Sentiment: Positive
Value investing is essentially about selecting cheap but fundamentally sound stocks. STNE, CSV, ASB & PFE boast low P/CF ratios.
Read More
3 Dividend Stocks to Buy and Hold for the Next Decade
Published: April 28, 2025 by: The Motley Fool
Sentiment: Positive
Many income investors would love to have a low-maintenance portfolio that doesn't require constant attention. They'd prefer to buy great stocks and rake in the dividends without any hiccups.
Read More
My 5 Top Stocks to Buy Right Now in This Highly Volatile Market
Published: April 28, 2025 by: The Motley Fool
Sentiment: Positive
Getting dizzy from the stock market's gyrations? Join the club.
Read More
Pfizer's Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer
Published: April 26, 2025 by: Business Wire
Sentiment: Neutral
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced results from the pivotal Phase 3 CREST trial of sasanlimab, an investigational anti-PD-1 monoclonal antibody (mAb), in combination with standard of care (SOC) Bacillus Calmette-Guérin (BCG) as induction therapy with or without maintenance in patients with BCG-naïve, high-risk non-muscle invasive bladder cancer (NMIBC). The trial met its primary endpoint of event-free survival (EFS) by investigator assessment, demonstrating a cli.
Read More
3 High Yield Dividend Stocks Under $25 to Buy and Hold Forever
Published: April 25, 2025 by: 24/7 Wall Street
Sentiment: Positive
As income and wealth inequality continue to divide Americans into two distinct classes and levels of wealth, those who are struggling to find investments that can outpace inflation and the growing costs of everyday life are hard-pressed to find options that fit their needs.
Read More
PFE vs. LLY: Which Stock Should Value Investors Buy Now?
Published: April 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Investors interested in Large Cap Pharmaceuticals stocks are likely familiar with Pfizer (PFE) and Eli Lilly (LLY). But which of these two stocks is more attractive to value investors?
Read More
Are Investors Undervaluing Pfizer (PFE) Right Now?
Published: April 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Read More
Pfizer Earnings Preview: Pharma May Plumb New Depths After Obesity Drug Debacle
Published: April 23, 2025 by: Seeking Alpha
Sentiment: Negative
Pfizer Inc.'s stock has performed poorly despite massive COVID-19 earnings, trading at a 12-year low due to flawed M&A deals and high debt levels. The discontinuation of danuglipron, a potential obesity drug, highlights Pfizer's struggle to develop successful new drugs, impacting its market position. Pfizer faces significant challenges including patent expiries, drug pricing controls, and questionable management decisions, casting doubt on its future performance.
Read More
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (April 2025)
Published: April 21, 2025 by: 24/7 Wall Street
Sentiment: Negative
Shares of Pfizer ( NYSE: PFE ) have been battered over the past month, falling by -16.44%, outpacing the market's loss of -9.44% over the same period.
Read More
3 High Yielding Dividend Stocks Near 52-Week Lows
Published: April 21, 2025 by: 24/7 Wall Street
Sentiment: Neutral
2025 hasn't been kind to investors amid rising concerns about a recession and tariffs.
Read More
Pfizer: Is The Dividend Yield Worth The Effort
Published: April 21, 2025 by: Seeking Alpha
Sentiment: Positive
Despite its historical underperformance and declining dividend growth trajectory, Pfizer's 7.63% dividend yield is attractive, making it a compelling income stock candidate. CEO Bourla's strategic focus on R&D, cost-cutting, and new revenue streams from acquisitions aims to mitigate upcoming revenue losses and drive future growth. Despite current challenges, Pfizer's robust cash flow, cost-saving initiatives, and potential new blockbusters by 2030 present a speculative but promising investment opportunity.
Read More
If You Like Schwab's SCHD, You Can't Miss These Stocks With Even Higher Yields
Published: April 18, 2025 by: 24/7 Wall Street
Sentiment: Positive
The Schwab U.S. Dividend Equity ETF (NYSEARCA:SCHD) has a reputation for being the go-to choice for income-focused investors who want both quality and yield.
Read More
Pfizer Abandons Its Leading Weight Loss Candidate. Should You Sell the Stock?
Published: April 18, 2025 by: The Motley Fool
Sentiment: Positive
Although it isn't the largest therapeutic area in the pharmaceutical industry, the market for weight loss therapies has caught fire in recent years. The leading medicines in this field include household names such as Wegovy and Zepbound, two drugs whose sales are rapidly growing.
Read More
Vaccine Stocks Rise on Growing Threat of Bird Flu Infections
Published: April 17, 2025 by: Zacks Investment Research
Sentiment: Negative
The Biden administration is reportedly in talks with vaccine makers Moderna (MRNA) and Pfizer (PFE) to develop bird flu vaccines over increasing fears of widespread transmission of the infection.
Read More
Viking Therapeutics' VK2735 Candidate Likely Boosted By Pfizer's Woes
Published: April 15, 2025 by: Seeking Alpha
Sentiment: Positive
13-week data from the Viking Therapeutics, Inc. phase 2 VENTURE-Oral Dosing trial using oral VK2735 for the treatment of patients with obesity, expected 2nd half of 2025. Pfizer's recent setbacks in weight-loss drugs may prompt it to consider acquiring VKTX, adding VK2735 and VK2809 to its pipeline. VK2735's dual administration routes and dual GLP-1/GIP agonist mechanism position it as a strong contender in the growing $37.94 billion anti-obesity market.
Read More
European pharma companies issue demands to stay in EU ahead of expected US tariffs
Published: April 15, 2025 by: Reuters
Sentiment: Negative
Nearly three dozen global pharmaceutical companies, in a letter to the head of the European Commission, demanded help to maintain operations in the EU despite threatened U.S. tariffs on imports, including measures to compensate them for the cost of pharmaceutical innovations, French business newspaper Les Echos reported on Tuesday.
Read More
Pfizer Halts Obesity Pill Development Amid Safety Concerns
Published: April 15, 2025 by: Zacks Investment Research
Sentiment: Neutral
PFE's decision to scrap the development of danuglipron comes after a study participant develops potential drug-induced liver injury.
Read More
The Tariff Game Just Changed: 7 Blue-Chip Bargains To Buy Now
Published: April 15, 2025 by: Seeking Alpha
Sentiment: Positive
Unprecedented Opportunities: Recent market panic has created deep discounts among world-class blue-chip companies trading at 52-week lows, offering up to 100% potential returns and secure yields approaching 8%. Trade War Realities: Despite severe pessimism driven by historic tariff increases (highest since 1909), the actual economic impact might be significantly less dire, potentially avoiding recession altogether. Institutional strategies, such as pensions and risk parity funds, may soon trigger substantial stock-buying due to automatic rebalancing. This would provide strong support and fuel market rallies from oversold conditions.
Read More
Trump Says Pharmaceutical Tariffs Coming in Near Future
Published: April 14, 2025 by: Bloomberg Markets and Finance
Sentiment: Negative
President Donald Trump said tariffs on pharmaceuticals will be coming in the “not too distant future” and fit in the category of tariffs imposed on cars, steel, and aluminum. Trump spoke with reporters Monday in the Oval Office.
Read More
Trump says US pharma tariffs coming in not-too-distant future
Published: April 14, 2025 by: Reuters
Sentiment: Negative
U.S. President Donald Trump said on Monday that he expects to impose tariffs on imported pharmaceuticals in the not-too-distant future.
Read More
Biotech Stock A Big Winner After Pfizer Halts Weight-Loss Drug
Published: April 14, 2025 by: Schaeffers Research
Sentiment: Positive
Viking Therapeutics Inc (NASDAQ:VKTX) stock is up 10.1% to trade at $24.42 today, and traded as high as $27.09 earlier in the session.
Read More
Pfizer discontinues development of weight loss pill
Published: April 14, 2025 by: Proactive Investors
Sentiment: Negative
Pfizer Inc (NYSE:PFE, ETR:PFE) announced it will discontinue the development of its experimental weight-loss pill, danuglipron, due to safety concerns. The company said on Monday that the decision comes after a clinical trial participant experienced a potential drug-induced liver injury, which resolved after stopping the medication.
Read More
Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
Published: April 11, 2025 by: CNBC
Sentiment: Negative
President Donald Trump's planned tariffs on pharmaceuticals imported into the U.S. could have wide-ranging consequences on the drug supply chain, manufacturers and American patients, some experts told CNBC. The tariffs could disrupt the complex pharmaceutical supply chain, potentially driving up the prices of drugs in the U.S. and exacerbating shortages of critical medicine.
Read More
About Pfizer Inc. (PFE)
- IPO Date 1972-06-01
- Website https://www.pfizer.com
- Industry Drug Manufacturers - General
- CEO Dr. Albert Bourla D.V.M., Ph.D.
- Employees 81000